Navigation Links
New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
Date:9/12/2007

already approved for the treatment of complicated skin and soft tissue infections (cSSTI) caused by Staphylococcus aureus and other Gram positive bacteria, including MRSA.(1) Clinical trials in cSSTI showed daptomycin had a faster time to cure (63% of patients successfully treated with daptomycin achieved a clinical cure within four to seven days versus 33% with comparators such as vancomyin and anti-staphylococcal penicillins).(6)

Pivotal trial data published in The New England Journal of Medicine supports the use of daptomycin in the treatment of bacteraemia and endocarditis caused by MRSA. The head-to-head study demonstrated daptomycin single agent therapy was as effective as dual agent comparator treatments and also has a favourable safety and tolerability profile with more creatine phosphokinase (CK) elevations but significantly fewer renal side effects reported versus comparator treatments.(2) The favourable safety profile is an important factor in severely ill patients.

A recent survey suggests that there is delay in patients receiving appropriate treatment for MRSA in approximately 50% of cases.(7) Delaying effective treatment for 48 hours can increase mortality as well as result in longer hospital stays, thus increasing the burden on the healthcare system.(8-11) Since Daptomycin is equally effective in treating MSSA and MRSA, it represents an important new empirical treatment choice for patients with MRSA bacteraemia associated with right sided endocarditis or complicated soft skin tissue infections.(2)

About the product

Daptomycin was first approved in the UK in March 2006 and received a positive Scottish Medicines Consortium (SMC) recommendation for its use in treating complicated skin and soft tissue infections (cSSTIs) in March 2006.

Last month, The Committee for Medical Products for Human Use (CHMP) gave extended approval to daptomycin for the use in right-sided infective endocarditis (RIE) due to Staphylococcus aureus an
'/>"/>

SOURCE Novartis Pharmaceuticals UK Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. Midwest life science stocks sizzle in a tepid first quarter
3. Morgridge Institute for Research seeks first CEO
4. Sonic Foundry reports first cash-positive quarter
5. Angel investors commit $12.7B in first half of `06
6. Aurora team implants Wisconsins first total artificial heart
7. First half of 2006 roundup: Big Pharma trumps biotech
8. GE announces first installation of Discovery VCT
9. GE Healthcare enjoys robust growth in first quarter
10. Madison asks for wireless bids; airport, downtown would be first
11. Tech Digest: Inacom, PKWare at Infosecurity, Firstlogic, Teklynx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Reston, VA (PRWEB) January 15, 2014 ... education have continued their sponsorship of an annual competition ... interest in, and access to, innovative STEM study. The ... , TEAMS: Tests of Engineering Aptitude, Mathematics, and ...
(Date:1/15/2014)... Arizona (PRWEB) January 15, 2014 2013 ... for Scottsdale’s Brain State Technologies®. They saw continued independent ... Medical Center who were awarded a $1 million grant ... published in “Brain and Behavior” a peer reviewed journal, ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Histogen, Inc., ... products of cells grown under simulated embryonic conditions, today ... agreement with Suneva Medical, Inc. for physician-dispensed aesthetic products ... , This agreement is an amendment to the ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Newly formed Advisory Board to advise on cancer screening ... mitochondrial DNA-based ... Inc. (OTC,Bulletin Board: TBIO) today announced that it has ... the latest developments and,scientific opportunities in cancer detection screening ...
... ... Use, LA JOLLA, Calif., Jan. 17 Stemagen, a privately ... in the world to create, and meticulously document, a cloned human,embryo ... Wood, M.D., Ph.D., a co-author of the,publication and a donor of ...
... Trial will also Support a Marketing Authorization Application in the ... ... Agennix Incorporated announced today,that the U.S. Food and Drug Administration ... evaluating its lead molecule,talactoferrin alfa, in combination with chemotherapy as first-line,treatment ...
Cached Biology Technology:Transgenomic, Inc. Forms Scientific Advisory Board 2Transgenomic, Inc. Forms Scientific Advisory Board 3Stemagen First to Create Cloned Human Embryos From Adult Cells 2Stemagen First to Create Cloned Human Embryos From Adult Cells 3Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 2Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 3Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 4Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 5
(Date:4/18/2014)... while feeding a world population predicted to reach ... approach to conservation that considers human-altered landscapes such ... and the natural habitat that supports it might ... where at least three-quarters of the land surface ... is vulnerable to human-caused impacts such as climate ...
(Date:4/18/2014)... to the story of how barnyard chickens came to be, ... journal Proceedings of the National Academy of Sciences . ... 200-2300 years ago in Europe, researchers report that just a ... different from the chickens we know today. , The results ... domestic chickens -- such as their yellowish skin -- only ...
(Date:4/18/2014)... Asteroid and comet impacts can cause widespread ecological ... even global scales. But new research from Brown University ... ancient life at the time of an impact. , ... has found fragments of leaves and preserved organic compounds ... in Argentina. The material could provide a snapshot of ...
Breaking Biology News(10 mins):Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Ancient DNA offers clues to how barnyard chickens came to be 2Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3
... form of skin cancer, can be successfully treated in some ... work and why they are only effective in some patients ... articles in the January 17 issue of the Journal of ... of immune cells called killer T cells that can attack ...
... with high-risk breast cancer treated with radical mastectomy and ... better survival outcomes with few long-term toxic effects, according ... appears in the January 19 issue of the Journal ... randomized radiation therapy trial was designed to determine the ...
... results of a recent U.S. study, investigators in Japan ... potentially life-threatening form of high blood pressure, as reported ... Infectious Diseases, now available online. , The researchers reported ... 8 (HHV-8), also known as the Kaposi's sarcoma virus, ...
Cached Biology News:Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer 2Association of herpesvirus with lung disorder questioned 2
Mouse monoclonal [IA-C6] to MHC Class II I Ab + Ad (FITC) ( Abpromise for all tested applications). Antigen: Tissue / cell preparation of Purified Mouse lymph node B cells...
...
... Series 4000 incorporates the critical design features ... in biomarker research. The Series 4000 delivers ... converting biomarker discoveries to biomarker assays all ... is designed to fit into the research ...
The piston kit includes 2 pistons to service one F10 pump of a BioLogic DuoFlow workstation....
Biology Products: